Skip to NavigationSkip to content

NICE promotes Professor Gillian Leng as its new Chief Executive

Published on 18/03/20 at 11:47am

NICE, the drug watchdog for the NHS in England and Wales, has announced that it has promoted Professor Gillian Leng to serve as its new Chief Executive.

She is set to replace current Chief Sir Andrew Dillon who will step down on 1 April, ending his tenure at the organisation he has led since 1999.

Professor Leng steps up from her role as Deputy Chief Executive, a position she has held since 2007, though she also holds the title of Director of Health and Social Care. She was selected for her new role by the non-executive members of NICE’s Board.

Sir Dillon remarked: “I am delighted that Gill has been appointed as NICE’s next Chief Executive. She is an outstanding leader and has all the qualities needed to lead the organisation into its third decade. I am entirely confident that NICE will be safe and successful in her hands.”

Professor Leng also commented on her own appointment: “Under Andrew’s leadership NICE has gained a formidable reputation both nationally and internationally as a world leader in guidance development. I am honoured and privileged to have been appointed as its second Chief Executive. I look forward to working with the Institute’s staff and stakeholders as we enter an exciting new chapter of innovative changes to deliver our portfolio of guidance into the hands of frontline staff in an easy and intuitive way.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches